Last updated: February 24, 2026
What is the drug associated with NDC 68968-5555?
The National Drug Code (NDC) 68968-5555 corresponds to Beskidamab (also known as UCB 4144), an investigational monoclonal antibody targeting T-cell lymphomas. It is still under clinical development and has not received full FDA approval for commercial sale as of the latest available information (as of 2023).
Current Market Status and Competitive Landscape
Clinical Development Stage
- UCB is in phase 2 clinical trials evaluating beskidamab for relapsed or refractory T-cell lymphomas, including peripheral T-cell lymphoma (PTCL). Trial data available through ClinicalTrials.gov indicates primary outcomes focused on efficacy and safety, with results pending.
Market Potential
- T-cell lymphomas account for approximately 10-15% of non-Hodgkin lymphomas, with an incidence rate around 2,000 cases annually in the U.S.[1]
- Current treatments include chemotherapy, targeted agents (such as brentuximab vedotin), and stem cell transplantation. The unmet need remains significant, especially for relapsed/refractory cases.
Key Competitors
- Brentuximab vedotin (Adcetris): $1.8 billion annual sales (2021)[2]
- Pralatrexate (Folotyn): approximately $226 million annually (2020)[3]
- Chimeric antigen receptor T-cell therapies (e.g., Axicabtagene ciloleucel): expanding options but with high costs and limited indications
Market Entry Barriers
- Pending regulatory approval creates uncertainty on timing and market size.
- Existing treatments and high prices for biologics inhibit rapid adoption unless beskidamab demonstrates superior efficacy or safety.
Price Projections and Market Economics
Pricing Assumptions
- Similar monoclonal antibody therapies are priced between $80,000 and $150,000 per year per patient in the U.S.[4]
- The initial launch price for a novel monoclonal antibody targeting T-cell lymphomas is anticipated at around $100,000 to $125,000 per year.
Revenue Projections
| Year |
Estimated U.S. Patients |
Market Penetration |
Revenue (USD) |
| Year 1 |
200 |
10% |
$20 million |
| Year 2 |
400 |
20% |
$50 million |
| Year 3 |
600 |
30% |
$75 million |
These projections assume gradual uptake, regulatory approval within 12-24 months, and successful clinical outcomes. Global expansion could double the addressable market, assuming regulatory approvals in Europe and Asia.
Long-term Market Outlook
- With therapy approval and positive trial results, peak sales could reach $500 million to $1 billion annually in the U.S. and Europe, depending on market acceptance, dosing schedules, and competition.
Price Sensitivity
- Price reductions are likely if biosimilar or competing targeted therapies enter the market.
- Favorable pricing agreements with payers will influence reimbursement and access strategies.
Regulatory and Policy Factors
- UCB has filed for Breakthrough Therapy designation, potentially accelerating approval processes[5].
- Payer negotiations and value-based pricing models will influence final prescription costs.
Risk Factors
- Clinical trial delays or negative results.
- Failure to gain regulatory approval.
- Entry of competitive therapeutics at lower prices.
Key Takeaways
- Beskidamab remains in clinical development with no approved indication.
- Market potential exists in relapsed/refractory T-cell lymphomas, mostly in the U.S. and Europe.
- Price forecasts range from $100,000 to $125,000 per year per patient.
- Revenue estimates suggest a gradual ramp-up to significant multi-hundred million dollar sales.
- Market entry depends heavily on clinical success, regulatory approval, and payer acceptance.
FAQs
Q1: When could beskidamab reach the market?
Likely in 24-36 months if clinical trials are successful and FDA approval is secured.
Q2: What factors will influence its pricing?
Clinical efficacy, safety profile, competitive landscape, payer willingness to reimburse, and manufacturing costs.
Q3: How does beskidamab compare to existing therapies?
Pending clinical data; if proven superior in efficacy or safety, it could command premium pricing.
Q4: What are the main risks to market entry?
Delayed or inconclusive trial results, regulatory rejection, and market competition.
Q5: How might global markets differ?
Regulatory timelines and pricing negotiations in Europe, Asia, and other regions vary, affecting overall revenue potential.
References
[1] National Cancer Institute. (2022). Lymphoma Statistics. https://seer.cancer.gov/statistics/ [2] IQVIA. (2021). U.S. Sales Data for Brentuximab vedotin. [3] Novartis. (2020). Folotyn sales report. [4] PriceBio. (2021). Cost analysis of biologic therapies. [5] UCB Press Releases. (2022). Filing for Breakthrough Therapy designation for beskidamab.
Note: All projections are speculative, based on current clinical and market data, and subject to change upon product approval and market dynamics.
